Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Total 13F shares
-
80,908,311
-
Share change
-
+7,258,463
-
Total reported value
-
$128,717,404
-
Put/Call ratio
-
35%
-
Price per share
-
$1.59
-
Number of holders
-
160
-
Value change
-
-$21,842,715
-
Number of buys
-
89
-
Number of sells
-
73
Institutional Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q1 2023
As of 31 Mar 2023,
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) was held by
160 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
80,908,311 shares.
The largest 10 holders included
WASATCH ADVISORS LP, BlackRock Inc., Balyasny Asset Management L.P., Meditor Group Ltd, VANGUARD GROUP INC, Bellevue Group AG, ARMISTICE CAPITAL, LLC, MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., and PLATINUM INVESTMENT MANAGEMENT LTD.
This page lists
161
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.